1BRIZEL D M,OVERGAARD J.Dose amifostine have a role in chemoradiation treatment-[J].Lancet Oncol,2003,4(6):378-381.
2ANNE P R,CURRAN W J Jr.A phase Ⅱ trial of subcutaneous amifostine and radiation therapy in patients with head and neck cancer[J].Semin Radiat Oncol,2002,2 (Suppl):18-19.
3CULY C R,SPENDER C M.Amifostine an update on its clinical status as a cytoprotectant in patients with cacer recieving chemotherapy on radiotherapy and its potential therapentic application in myelodysplastic syndrom[J].Drugs,2001,61(5):641-684.
6ACOSTA J C,RICHARD C,DELGADO M D,et al.Amifostine impairs p53-mediated apoptosis of human myeloid leukemia cells[J].Mol Cancer Ther,2003,2(9):893-900.
7LEE E J,GERHOLD M,PALMER M W.P53 protein regulates the effects of amifostine on apoptosis,cell cycle progression,and cytoprotection[J].Br J Cancer,2003,88(5):754-759.
8KATAOKA Y,MURLEY J S,KHODAREV N N.Activation of the nuclear transcription factor kappaB (NFkappaB) and differential gene expression in U87 glioma cells after exposure to the cytoprotector amifostine[J].Int J Radiat Oncol Biol Phys,2002,53(1):180-189.
9GRDINA D J,MURLEY J S,KATAOKA Y E.Delationslips between cytoprotection and mutation prevention by WR-1065[J].Mil Med,2002,167(92 Suppl):51-53.
10KINTZEL P E.Anticancer drug-induced kiney disorders[J].Drug Saf,2001,24(1):19-138.
2[1]Capizzi RL. Amifostine:the preclinical basis for broadspectrum selective cytoprotection of normal tissue from cytotoxic therapies [J]. Semin Oncol, 1996,23 (4supple 8):2-17.
3[2]Shuchter LM. Guidelines for the administration of amifostine [J]. Semin Oncol, 1996,23 (4 supple 8) : 40 -43.
4[3]Capizzi RL. The preclinical basis for broad-spectrum selective cytoprotect-ion of normal tissues form cytotoxic therapies by amifostine [J]. Semin Oncol, 1999,26(2 supple 7) :3-21.
6[5]Thomas Budd G. Amifostine and chemotherapy-relatedthrombocytoperia [J ]. Semin Oncol, 1996, 23 (4supple 8) :49-52.
7[6]Spencer CM ,Goa KL. Amifostine :a review of its pharmocodynamic and pharmokinetic properties ,and therapeutic potential as a radioprotector and cytotoxic chemoprotector [J]. Drug, 1995,50(6): 1001 - 1031.
8[7]Kemp G,Rose P,Lurain J,et al. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer [J]. J Clin Oncol, 1996,14 : 2101 - 2112.
9[8]Bohuslavizki KH,Brennar W,Klutmann S,et al. Radioprotection of salivary glands by amifostine in highdose radioiodine therapy[J]. J Nul Med, 1998,39 (7):1237-1242.
10[9]Buntzel J,Kuttnerk,Forhlich D,et al. Selective cytoprotection with amifostine in concurrent radiochemotherapy for head nd neck cancer[J]. Ann Oncol,1998,9(5) :505- 509.
